Ipamorelin vs Sermorelin: Mechanism and Dosing Compared

Ipamorelin and sermorelin both turn up in research discussions of growth hormone, and the shared goal — stimulating pituitary GH release — makes it easy to assume they work the same way. Ipamorelin vs sermorelin is really a comparison across two different receptor pathways, one of which once had a commercial FDA-approved product behind it and no longer does, and one of which never has. This reference lines up what separates ipamorelin and sermorelin and what stays identical in the reconstitution math. It is written for research and educational purposes only and is not medical advice.

What separates ipamorelin and sermorelin

The difference is mechanism, not potency. Ipamorelin is a growth hormone secretagogue that acts on the ghrelin receptor, prompting the pituitary to release growth hormone through that pathway. Sermorelin corresponds to GRF(1-29), the first 29 amino acids of natural human GHRH, and acts on the separate GHRH receptor. Ipamorelin has no GHRH-receptor activity of its own, and sermorelin has no secretagogue activity on the ghrelin receptor — each compound works through exactly one of the two pathways, not both. Because the pathways are separate, their effects are commonly described in the research literature as additive rather than redundant, which is the same rationale that underlies pairing a GHRH analog with ipamorelin in a single research protocol.

Sermorelin also carries a structural limitation ipamorelin doesn't share: as an unmodified GHRH fragment, it clears from circulation quickly — research literature commonly describes its circulating activity in terms of minutes. Ipamorelin's short-acting profile is a separate property of its own structure. Neither compound's reconstitution or storage handling changes because of any of this. Both arrive as lyophilized powder and dissolve the same way once bacteriostatic water is added.

Regulatory and research status

This is where ipamorelin and sermorelin diverge in history, even though neither is currently approved. Sermorelin was previously sold in the United States under an FDA-approved brand name, Geref, for evaluating growth hormone secretion. That commercial product was later discontinued by its manufacturer, and sermorelin used in research today is not sold as an FDA-approved drug product. Ipamorelin has never had an FDA-approved pharmaceutical formulation for any indication and remains a research compound studied in preclinical and limited early human research.

Neither compound is discussed here as something to take. This article covers the underlying chemistry and reconstitution arithmetic, not a use recommendation, and sermorelin's earlier approval history doesn't change how either peptide is supplied or handled by researchers now.

Vial formats and typical concentrations

Both peptides reach researchers as lyophilized powder in single-peptide vials. Reference points below are common because they land typical research doses on clean, easy-to-read syringe marks:

Peptide	Common vial size	Reference water volume	Concentration
Ipamorelin	5 mg	2 mL	2.5 mg/mL (2500 mcg/mL)
Sermorelin	5 mg	2 mL	2.5 mg/mL (2500 mcg/mL)

These are reference points, not requirements. The peptide calculator recalculates concentration and syringe units for any vial size and water volume entered, for either compound.

Worked example: same formula, different receptor targets

The formula doesn't change based on which peptide, or which receptor pathway, is in the vial: concentration equals mass divided by water volume, and syringe units equal that volume in mL multiplied by 100 on a U-100 insulin syringe.

Ipamorelin. A 5 mg vial with 2 mL of bacteriostatic water is 5 ÷ 2 = 2.5 mg/mL, or 2500 mcg/mL. A 300 mcg dose is 300 ÷ 2500 = 0.12 mL, or 0.12 × 100 = 12 units.

Sermorelin. A 5 mg vial with 2 mL of bacteriostatic water is also 5 ÷ 2 = 2.5 mg/mL, or 2500 mcg/mL. A 500 mcg dose is 500 ÷ 2500 = 0.2 mL, or 0.2 × 100 = 20 units.

Both vials happen to land on the same concentration in this example, but the unit result still depends on the target dose entered for each — 12 units for ipamorelin's 300 mcg and 20 units for sermorelin's 500 mcg. Change either compound's vial size, water volume, or target dose, and its units shift independently of the other.

Why one calculator covers both

Here's how we see it: the step where a research dose actually goes wrong isn't the injection, it's the reconstitution math. A U-100 insulin syringe always reads 100 units per mL, so the mcg-per-unit depends entirely on how much water went into the vial — a fact that holds whether the vial contains ipamorelin or sermorelin. Get the water volume wrong and every draw after inherits the same error, regardless of which receptor pathway the peptide targets. That's why a single free peptide calculator, built on the mass-divided-by-volume formula, covers both compounds without any peptide-specific adjustment. For the full mixing walkthrough, see how to reconstitute peptides.

Where the comparison breaks down

The reconstitution math is identical for ipamorelin and sermorelin; the compounds and their histories are not. Sermorelin's earlier FDA approval, under the Geref brand, was discontinued by its manufacturer and doesn't carry over to how sermorelin is supplied or discussed today — it is not evidence of a current approval. Ipamorelin, by contrast, has never carried any FDA approval at all. And because the two compounds act on separate receptors, a dosing frequency referenced for one says nothing about the appropriate frequency for the other — sermorelin's fast clearance as an unmodified GHRH fragment is a structural property of that molecule, not something ipamorelin inherits. Treating the two as interchangeable because both raise growth hormone, or assuming sermorelin's history amounts to a current approval, are the two most common mix-ups in how this comparison gets discussed.

Common mistakes

• Assuming sermorelin's past FDA approval still applies. It doesn't. The Geref brand was discontinued, and sermorelin used in research today has no current FDA-approved formulation — the same status as ipamorelin.
• Treating the two as substitutes because both raise growth hormone. They reach that outcome through separate receptors, and a research protocol built around one doesn't automatically transfer to the other.
• Confusing mg and mcg. Ipamorelin and sermorelin doses are described in milligrams or micrograms depending on the source. 1 mg equals 1,000 mcg, and misreading one for the other produces a 1,000x error.
• Shaking the vial. Swirl gently instead — shaking can degrade the peptide.
• Reusing a water volume across vial sizes. A water volume that gives 2.5 mg/mL for a 5 mg vial gives a different concentration on a 2 mg or 10 mg vial. Recalculate rather than reusing a number from memory.
• Assuming a dosing frequency from one compound applies to the other. Sermorelin's fast clearance as an unmodified GHRH fragment and ipamorelin's own short-acting profile are separate structural properties. Neither interval transfers to the other compound by default.

Related

For the ipamorelin-specific syringe-unit walkthrough, see the ipamorelin dosage calculator guide. For sermorelin compared against a longer-acting, currently-approved GHRH analog, see tesamorelin vs sermorelin. Or enter your own vial size, water volume, and target dose into the peptide dosage calculator to see the exact syringe units for either compound.